Does hepatic steatosis affect drug metabolizing enzymes in the liver?

Current Drug Metabolism

Volumn 12, Issue 1, 2011, Pages 24-34

  Buechler, Christa ^a   Weiss, Thomas S ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Drug metabolizing enzymes; Hepatic steatosis; Steatohepatitis

Indexed keywords

ALCOHOL; AROMATIC HYDROCARBON RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; DRUG METABOLIZING ENZYME; FARNESOID X RECEPTOR; GLUTATHIONE; LIVER X RECEPTOR; METFORMIN; ORGANIC ANION TRANSPORTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PREGNANE X RECEPTOR; ROSIGLITAZONE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NF E2 P45 SUBUNIT; XENOBIOTIC AGENT;

ARTICLE; BILIARY EXCRETION; CONJUGATION; DETOXIFICATION; DRUG METABOLISM; GLUCURONIDATION; IN VITRO STUDY; LIVER DISEASE; LIVER METABOLISM; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PROTEIN EXPRESSION; SULFATION;

ANIMALS; BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; FATTY LIVER; GENE EXPRESSION REGULATION; HUMANS; LIVER; XENOBIOTICS;

EID: 79951633215     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920011794520035     Document Type: Article

References (139)

1. Gastaldelli, A.; Natali, A.; Vettor, R.; Corradini, S. G. Insulin resistance, adipose depots and gut: interactions and pathological implications. Dig. Liver Dis., 2010, 42(5), 310-319.
2. Marchesini, G.; Marzocchi, R.; Agostini, F.; Bugianesi, E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr. Opin. Lipidol., 2005, 16(4), 421-427. (Pubitemid 41017626)
3. Schaffler, A.; Scholmerich, J.; Buchler, C. Mechanisms of disease: adipocytokines and visceral adipose tissue-emerging role in nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol., 2005, 2(6), 273-280. (Pubitemid 40895403)
4. Neuschwander-Tetri, B. A.; Caldwell, S. H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology, 2003, 37(5), 1202-1219. (Pubitemid 36538699)
5. Valenti, L.; Fracanzani, A. L.; Fargion, S. The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease? Semin Immunopathol., 2009, 31(3), 359-369.
6. Ekstedt, M.; Franzen, L. E.; Holmqvist, M.; Bendtsen, P.; Mathiesen, U. L.; Bodemar, G.; Kechagias, S. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand. J. Gastroenterol., 2009, 44(3), 366-374.
7. Caballeria, L.; Pera, G.; Auladell, M. A.; Toran, P.; Munoz, L.; Miranda, D.; Aluma, A.; Casas, J. D.; Sanchez, C.; Gil, D.; Auba, J.; Tibau, A.; Canut, S.; Bernad, J.; Aizpurua, M. M. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur. J. Gastroenterol. Hepatol., 2010, 22(1), 24-32.
8. Choi, S. S.; Diehl, A. M. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr. Opin. Lipidol., 2008, 19(3), 295-300. (Pubitemid 351653569)
9. Browning, J. D.; Horton, J. D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest, 2004, 114(2), 147-152. (Pubitemid 39071617)
10. Gil-Campos, M.; Canete, R. R.; Gil, A. Adiponectin, the missing link in insulin resistance and obesity. Clin. Nutr., 2004, 23(5), 963-974. (Pubitemid 39243008)
11. Clark, J. M.; Brancati, F. L.; Diehl, A. M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol., 2003, 98(5), 960-967. (Pubitemid 36733754)
12. Clark, J. M. The epidemiology of nonalcoholic fatty liver disease in adults. J. Clin. Gastroenterol., 2006, 40 Suppl 1S 5-10.
13. Preiss, D.; Sattar, N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin. Sci. (Lond), 2008, 115(5), 141-150.
14. Erickson, S. K. Nonalcoholic fatty liver disease. J. Lipid Res., 2009, 50 (SupplS), 412-416.
15. Han, J. C.; Lawlor, D. A.; Kimm, S. Y. Childhood obesity. Lancet, 2010, 375(9727), 1737-1748.
16. Omagari, K.; Kadokawa, Y.; Masuda, J.; Egawa, I.; Sawa, T.; Hazama, H.; Ohba, K.; Isomoto, H.; Mizuta, Y.; Hayashida, K.; Murase, K.; Kadota, T.; Murata, I.; Kohno, S. Fatty liver in nonalcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol, 2002, 17(10), 1098-1105. (Pubitemid 35013966)
17. Wu, H. Y.; Xu, S. Y.; Chen, L. L.; Zhang, H. F. Waist to height ratio as a predictor of abdominal fat distribution in men. Chin. J. Physiol., 2009, 52(6), 441-445.
18. Micklesfield, L. K.; Evans, J.; Norris, S. A.; Lambert, E. V.; Jennings, C.; Joffe, Y.; Levitt, N. S.; Goedecke, J. H. Dual-energy X-ray absorptiometry and anthropometric estimates of visceral fat in Black and White South African Women. Obesity (Silver Spring), 2010, 18(3), 619-624.
19. Fontana, L.; Eagon, J. C.; Trujillo, M. E.; Scherer, P. E.; Klein, S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes, 2007, 56(4), 1010-1013. (Pubitemid 46525079)
20. Wiest, R.; Weigert, J.; Wanninger, J.; Neumeier, M.; Bauer, S.; Schmidhofer, S.; Farkas, S.; Scherer, M. N.; Schaffler, A.; Scholmerich, J.; Buechler, C. Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis. Cytokine, 2010, in press.
21. Andus, T.; Bauer, J.; Gerok, W. Effects of cytokines on the liver. Hepatology, 1991, 13(2), 364-375.
22. Sabio, G.; Das, M.; Mora, A.; Zhang, Z.; Jun, J. Y.; Ko, H. J.; Barrett, T.; Kim, J. K.; Davis, R. J. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science, 2008, 322(5907), 1539-1543.
23. Goossens, G. H. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol. Behav., 2008, 94(2), 206-218. (Pubitemid 351615418)
24. Fabbrini, E.; Sullivan, S.; Klein, S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology, 2010, 51(2), 679-689.
25. Tsochatzis, E. A.; Papatheodoridis, G. V.; Archimandritis, A. J. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm., 2009, 2009, 831670.
26. Weigert, J.; Neumeier, M.; Wanninger, J.; Wurm, S.; Kopp, A.; Schober, F.; Filarsky, M.; Schaffler, A.; Zeitoun, M.; Aslanidis, C.; Buechler, C. Reduced response to adiponectin and lower abundance of adiponectin receptor proteins in type 2 diabetic monocytes. FEBS Lett., 2008, 582(12), 1777-1782.
27. Polyzos, S. A.; Kountouras, J.; Zavos, C.; Deretzi, G. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of literature. J Clin. Gastroenterol., 2011, 45(1), 50-54..
28. Gastaldelli, A.; Harrison, S. A.; Belfort-Aguilar, R.; Hardies, L. J.; Balas, B.; Schenker, S.; Cusi, K. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology, 2009, 50(4), 1087-1093.
29. Abernethy, D. R.; Greenblatt, D. J.; Divoll, M.; Shader, R. I. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J. Lab. Clin. Med., 1983, 101(6), 873-880. (Pubitemid 13100682)
30. Hanley, M. J.; Abernethy, D. R.; Greenblatt, D. J. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet., 2010, 49(2), 71-87.
31. Schattenberg, J. M.; Galle, P. R. Animal models of non-alcoholic steatohepatitis: of mice and man. Dig. Dis., 2010, 28(1), 247-254.
32. Hewitt, N. J.; Lechon, M. J.; Houston, J. B.; Hallifax, D.; Brown, H. S.; Maurel, P.; Kenna, J. G.; Gustavsson, L.; Lohmann, C.; Skonberg, C.; Guillouzo, A.; Tuschl, G.; Li, A. P.; LeCluyse, E.; Groothuis, G. M.; Hengstler, J. G. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev., 2007, 39(1), 159-234.
33. Donato, M. T.; Lahoz, A.; Jimenez, N.; Perez, G.; Serralta, A.; Mir, J.; Castell, J. V.; Gomez-Lechon, M. J. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab. Dispos., 2006, 34(9), 1556-1562. (Pubitemid 44285398)
34. Starley, B. Q.; Calcagno, C. J.; Harrison, S. A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology, 2010, 51(5), 1820-1832.
35. Shu, Y.; Brown, C.; Castro, R. A.; Shi, R. J.; Lin, E. T.; Owen, R. P.; Sheardown, S. A.; Yue, L.; Burchard, E. G.; Brett, C. M.; Giacomini, K. M. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther., 2008, 83(2), 273-280.
36. Kullak-Ublick, G. A.; Stieger, B.; Hagenbuch, B.; Meier, P. J. Hepatic transport of bile salts. Semin. Liver Dis., 2000, 20(3), 273-292.
37. Mennone, A.; Soroka, C. J.; Cai, S. Y.; Harry, K.; Adachi, M.; Hagey, L.; Schuetz, J. D.; Boyer, J. L. Mrp4-/-mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology, 2006, 43(5), 1013-1021. (Pubitemid 43724626)
38. Borst, P.; de Wolf, C.; van de Wetering, K. Multidrug resistanceassociated proteins 3, 4, and 5. Pflugers Arch., 2007, 453(5), 661-673.
39. Nakakariya, M.; Shimada, T.; Irokawa, M.; Maeda, T.; Tamai, I. Identification and species similarity of OATP transporters responsible for hepatic uptake of beta-lactam antibiotics. Drug Metab. Pharmacokinet., 2008, 23(5), 347-355.
40. Geier, A.; Dietrich, C. G.; Grote, T.; Beuers, U.; Prufer, T.; Fraunberger, P.; Matern, S.; Gartung, C.; Gerbes, A. L.; Bilzer, M. Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J. Hepatol., 2005, 43(6), 1021-1030. (Pubitemid 41627988)
41. Martin, I. V.; Schmitt, J.; Minkenberg, A.; Mertens, J. C.; Stieger, B.; Mullhaupt, B.; Geier, A. Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice. Biol. Chem., 2010, 391(12), 1441-1449.
42. Fisher, C. D.; Lickteig, A. J.; Augustine, L. M.; Oude Elferink, R. P.; Besselsen, D. G.; Erickson, R. P.; Cherrington, N. J. Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur. J. Pharmacol., 2009, 613 (1-3), 119-127.
43. Lickteig, A. J.; Fisher, C. D.; Augustine, L. M.; Aleksunes, L. M.; Besselsen, D. G.; Slitt, A. L.; Manautou, J. E.; Cherrington, N. J. Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab. Dispos., 2007, 35(10), 1970-1978. (Pubitemid 47481594)
44. Kalhan, S. C.; Guo, L.; Edmison, J.; Dasarathy, S.; McCullough, A. J.; Hanson, R. W.; Milburn, M. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism, 2010, in press.
45. Puri, P.; Baillie, R. A.; Wiest, M. M.; Mirshahi, F.; Choudhury, J.; Cheung, O.; Sargeant, C.; Contos, M. J.; Sanyal, A. J. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology, 2007, 46(4), 1081-1090. (Pubitemid 350144772)
46. Dias, V.; Ribeiro, V. The expression of the solute carriers NTCP and OCT-1 is regulated by cholesterol in HepG2 cells. Fundam Clin. Pharmacol., 2007, 21(4), 445-450. (Pubitemid 47084033)
47. Otsuka, M.; Matsumoto, T.; Morimoto, R.; Arioka, S.; Omote, H.; Moriyama, Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl. Acad. Sci. USA, 2005, 102(50), 17923-17928. (Pubitemid 41798478)
48. Nakata, K.; Tanaka, Y.; Nakano, T.; Adachi, T.; Tanaka, H.; Kaminuma, T.; Ishikawa, T. Nuclear receptor-mediated transcriptional regulation in Phase I, II, and III xenobiotic metabolizing systems. Drug. Metab. Pharmacokinet., 2006, 21(6), 437-457.
49. Pizarro, M.; Balasubramaniyan, N.; Solis, N.; Solar, A.; Duarte, I.; Miquel, J. F.; Suchy, F. J.; Trauner, M.; Accatino, L.; Ananthanarayanan, M.; Arrese, M. Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function. Gut, 2004, 53(12), 1837-1843. (Pubitemid 39556907)
50. Diao, L.; Li, N.; Brayman, T. G.; Hotz, K. J.; Lai, Y. Regulation of MRP2/ABCC2 and BSEP/ABCB11 expression in sandwich cultured human and rat hepatocytes exposed to inflammatory cytokines TNF-{alpha}, IL-6, and IL-1{beta}. J. Biol. Chem., 2010, 285(41), 31185-31192.
51. Nowicki, M. T.; Aleksunes, L. M.; Sawant, S. P.; Dnyanmote, A. V.; Mehendale, H. M.; Manautou, J. E. Renal and hepatic transporter expression in type 2 diabetic rats. Drug Metab. Lett., 2008, 2(1), 11-17. (Pubitemid 351411256)
52. Aranha, M. M.; Cortez-Pinto, H.; Costa, A.; da Silva, I. B.; Camilo, M. E.; de Moura, M. C.; Rodrigues, C. M. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur. J. Gastroenterol. Hepatol., 2008, I (6), 519-525. (Pubitemid 351667892)
53. Bozina, N.; Bradamante, V.; Lovric, M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh. Hig. Rada. Toksikol., 2009, 60(2), 217-242.
54. Blouin, R. A.; Bandyopadhyay, A. M.; Chaudhary, I.; Robertson, L. W.; Gemzik, B.; Parkinson, A. Cytochrome P450 2B enzyme (CYP2B) induction defect following phenobarbital treatment in the fa/fa Zucker rat: molecular characterization. Arch. Biochem. Biophys., 1993, 303(2), 313-320. (Pubitemid 23199827)
55. Saito, K.; Kobayashi, K.; Mizuno, Y.; Fukuchi, Y.; Furihata, T.; Chiba, K. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists induce constitutive androstane receptor (CAR) and cytochrome P450 2B in rat primary hepatocytes. Drug Metab. Pharmacokinet., 2010, 25(1), 108-111.
56. Fisher, C. D.; Jackson, J. P.; Lickteig, A. J.; Augustine, L. M.; Cherrington, N. J. Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch. Toxicol., 2008, 82(12), 959-964.
57. Robertson, G.; Leclercq, I.; Farrell, G. C. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am. J. Physiol. Gastrointest. Liver Physiol., 2001, 281(5), G1135-1139.
58. Weltman, M. D.; Farrell, G. C.; Liddle, C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology, 1996, 111(6), 1645-1653. (Pubitemid 26404230)
59. Gomez-Lechon, M. J.; Jover, R.; Donato, M. T. Cytochrome p450 and steatosis. Curr Drug Metab, 2009, 10(7), 692-699.
60. Niemela, O.; Parkkila, S.; Juvonen, R. O.; Viitala, K.; Gelboin, H. V.; Pasanen, M. Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. J. Hepatol., 2000, 33(6), 893-901.
61. Videla, L. A.; Rodrigo, R.; Orellana, M.; Fernandez, V.; Tapia, G.; Quinones, L.; Varela, N.; Contreras, J.; Lazarte, R.; Csendes, A.; Rojas, J.; Maluenda, F.; Burdiles, P.; Diaz, J. C.; Smok, G.; Thielemann, L.; Poniachik, J. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin. Sci. (Lond)., 2004, 106(3), 261-268. (Pubitemid 38365832)
62. Mitsuyoshi, H.; Yasui, K.; Harano, Y.; Endo, M.; Tsuji, K.; Minami, M.; Itoh, Y.; Okanoue, T.; Yoshikawa, T. Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol Res, 2009, 39(4), 366-373.
63. Kolwankar, D.; Vuppalanchi, R.; Ethell, B.; Jones, D. R.; Wrighton, S. A.; Hall, S. D.; Chalasani, N. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol. Hepatol., 2007, 5(3), 388-393. (Pubitemid 46401527)
64. Fisher, C. D.; Lickteig, A. J.; Augustine, L. M.; Ranger-Moore, J.; Jackson, J. P.; Ferguson, S. S.; Cherrington, N. J. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab. Dispos., 2009, 37(10), 2087-2094.
65. Donato, M. T.; Jimenez, N.; Serralta, A.; Mir, J.; Castell, J. V.; Gomez-Lechon, M. J. Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. Toxicol. In Vitro, 2007, 21(2), 271-276. (Pubitemid 46205072)
66. Yang, J.; Hao, C.; Yang, D.; Shi, D.; Song, X.; Luan, X.; Hu, G.; Yan, B. Pregnane X receptor is required for interleukin-6-mediated down-regulation of cytochrome P450 3A4 in human hepatocytes. Toxicol. Lett., 2010, 197(3), 219-226.
67. Stepanova, M.; Hossain, N.; Afendy, A.; Perry, K.; Goodman, Z. D.; Baranova, A.; Younossi, Z. Hepatic gene expression of Caucasian and African-American patients with obesity-related nonalcoholic fatty liver disease. Obes. Surg., 2010, 20(5), 640-650.
68. Bell, L. N.; Temm, C. J.; Saxena, R.; Vuppalanchi, R.; Schauer, P.; Rabinovitz, M.; Krasinskas, A.; Chalasani, N.; Mattar, S. G. Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann Surg, 2010, 251(6), 1041-1048.
69. Gong, P.; Cederbaum, A. I.; Nieto, N. Increased expression of cytochrome P450 2E1 induces heme oxygenase-1 through ERK MAPK pathway. J. Biol. Chem., 2003, 278(32), 29693-29700. (Pubitemid 36962355)
70. Gong, P.; Cederbaum, A. I.; Nieto, N. Heme oxygenase-1 protects HepG2 cells against cytochrome P450 2E1-dependent toxicity. Free Radic. Biol. Med., 2004, 36(3), 307-318. (Pubitemid 38130229)
71. Singh, R.; Wang, Y.; Schattenberg, J. M.; Xiang, Y.; Czaja, M. J. Chronic oxidative stress sensitizes hepatocytes to death from 4-hydroxynonenal by JNK/c-Jun. overactivation. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 297(5), G907-917.
72. Ricchi, M.; Odoardi, M. R.; Carulli, L.; Anzivino, C.; Ballestri, S.; Pinetti, A.; Fantoni, L. I.; Marra, F.; Bertolotti, M.; Banni, S.; Lonardo, A.; Carulli, N.; Loria, P. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J. Gastroenterol. Hepatol., 2009, 24(5), 830-840.
73. Wobser, H.; Dorn, C.; Weiss, T. S.; Amann, T.; Bollheimer, C.; Buttner, R.; Scholmerich, J.; Hellerbrand, C. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res, 2009, 19(8), 996-1005.
74. Yao, H. T.; Chang, Y. W.; Lan, S. J.; Chen, C. T.; Hsu, J. T.; Yeh, T. K. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci, 2006, 79(26), 2432-2440. (Pubitemid 44781104)
75. Murray, M. Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. Curr. Drug Metab., 2006, 7(1), 67-81.
76. Kitamura, S.; Sugihara, K.; Ohta, S. Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab. Pharmacokinet., 2006, 21(2), 83-98.
77. Johns, D. G. Human liver aldehyde oxidase: differential inhibition of oxidation of charged and uncharged substrates. J. Clin. Invest., 1967, 46(9), 1492-1505.
78. Kundu, T. K.; Hille, R.; Velayutham, M.; Zweier, J. L. Characterization of superoxide production from aldehyde oxidase: an important source of oxidants in biological tissues. Arch. Biochem. Biophys., 2007, 460(1), 113-121. (Pubitemid 46505003)
79. Sreekumar, R.; Rosado, B.; Rasmussen, D.; Charlton, M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology, 2003, 38(1), 244-251. (Pubitemid 36775817)
80. Neumeier, M.; Weigert, J.; Schaffler, A.; Weiss, T. S.; Schmidl, C.; Buttner, R.; Bollheimer, C.; Aslanidis, C.; Scholmerich, J.; Buechler, C. Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro. Biochem. Biophys. Res. Commun., 2006, 350(3), 731-735. (Pubitemid 44547907)
81. Garattini, E.; Fratelli, M.; Terao, M. Mammalian aldehyde oxidases: genetics, evolution and biochemistry. Cell Mol. Life Sci., 2008, 65 (7-8), 1019-1048.
82. Nakamuta, M.; Kohjima, M.; Morizono, S.; Kotoh, K.; Yoshimoto, T.; Miyagi, I.; Enjoji, M. Evaluation of fatty acid metabolismrelated gene expression in nonalcoholic fatty liver disease. Int. J. Mol. Med., 2005, 16(4), 631-635.
83. Kohjima, M.; Enjoji, M.; Higuchi, N.; Kato, M.; Kotoh, K.; Yoshimoto, T.; Fujino, T.; Yada, M.; Yada, R.; Harada, N.; Takayanagi, R.; Nakamuta, M. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int. J. Mol. Med., 2007, 20(3), 351-358.
84. Sigruener, A.; Buechler, C.; Orso, E.; Hartmann, A.; Wild, P. J.; Terracciano, L.; Roncalli, M.; Bornstein, S. R.; Schmitz, G. Human aldehyde oxidase 1 interacts with ATP-binding cassette transporter-1 and modulates its activity in hepatocytes. Horm. Metab. Res., 2007, 39(11), 781-789. (Pubitemid 350206898)
85. Yang, Y.; Jiang, Y.; Wang, Y.; An, W. Suppression of ABCA1 by unsaturated fatty acids leads to lipid accumulation in HepG2 cells. Biochimie., 2010, 92(8), 958-963.
86. Cashman, J. R.; Zhang, J. Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation. Drug Metab Dispos, 2002, 30(10), 1043-1052.
87. Zhang, W. V.; Ramzan, I.; Murray, M. Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis. J. Pharmacol. Exp. Ther., 2007, 322(2), 770-777. (Pubitemid 47105816)
88. Gyamfi, M. A.; Damjanov, I.; French, S.; Wan, Y. J. The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury. Biochem. Pharmacol., 2008, 75(4), 981-995. (Pubitemid 351174111)
89. Buechler, C.; Schaffler, A.; Johann, M.; Neumeier, M.; Kohl, P.; Weiss, T.; Wodarz, N.; Kiefer, P.; Hellerbrand, C. Elevated adiponectin serum levels in patients with chronic alcohol abuse rapidly decline during alcohol withdrawal. J. Gastroenterol. Hepatol., 2009, 24(4), 558-563.
90. Cope, K.; Risby, T.; Diehl, A. M. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology, 2000, 119(5), 1340-1347.
91. Baker, S. S.; Baker, R. D.; Liu, W.; Nowak, N. J.; Zhu, L. Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS One, 2010, 5(3), e9570.
92. Miele, L.; Valenza, V.; La Torre, G.; Montalto, M.; Cammarota, G.; Ricci, R.; Masciana, R.; Forgione, A.; Gabrieli, M. L.; Perotti, G.; Vecchio, F. M.; Rapaccini, G.; Gasbarrini, G.; Day, C. P.; Grieco, A. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology, 2009, 49(6), 1877-1887.
93. Zamek-Gliszczynski, M. J.; Hoffmaster, K. A.; Nezasa, K.; Tallman, M. N.; Brouwer, K. L. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur. J. Pharm. Sci., 2006, 27(5), 447-486. (Pubitemid 43363339)
94. Younossi, Z. M.; Baranova, A.; Ziegler, K.; Del Giacco, L.; Schlauch, K.; Born, T. L.; Elariny, H.; Gorreta, F.; Van Meter, A.; Younoszai, A.; Ong, J. P.; Goodman, Z.; Chandhoke, V. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology, 2005, 42(3), 665-674. (Pubitemid 41233660)
95. Younossi, Z. M.; Gorreta, F.; Ong, J. P.; Schlauch, K.; Giacco, L. D.; Elariny, H.; Van Meter, A.; Younoszai, A.; Goodman, Z.; Baranova, A.; Christensen, A.; Grant, G.; Chandhoke, V. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int., 2005, 25(4), 760-771. (Pubitemid 41038658)
96. Duan, X. Y.; Zhao, H. P.; Fan, J. G. Dynamic expression of hepatic thioredoxin mRNA in rats with non-alcoholic fatty liver disease. J. Dig. Dis., 2010, 11(2), 94-100.
97. Kirpich, I. A.; Gobejishvili, L. N.; Homme, M. B.; Waigel, S.; Cave, M.; Arteel, G.; Barve, S. S.; McClain, C. J.; Deaciuc, I. V. Integrated hepatic transcriptome and proteome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease. J. Nutr. Biochem., 2011, 22(1), 28-45.
98. Kwon do, Y.; Jung, Y. S.; Kim, S. J.; Park, H. K.; Park, J. H.; Kim, Y. C. Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats. J. Nutr., 2009, 139(1), 63-68.
99. Dominy, J. E., Jr.; Hwang, J.; Stipanuk, M. H. Overexpression of cysteine dioxygenase reduces intracellular cysteine and glutathione pools in HepG2/C3A cells. Am. J. Physiol. Endocrinol. Metab., 2007, 293(1), E62-69. (Pubitemid 47105917)
100. Wortham, M.; He, L.; Gyamfi, M.; Copple, B. L.; Wan, Y. J. The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet. Dig. Dis. Sci., 2008, 53(10), 2761-2774.
101. Osabe, M.; Sugatani, J.; Fukuyama, T.; Ikushiro, S.; Ikari, A.; Miwa, M. Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferatoractivated receptor alpha in male rats fed a high-fat and high-sucrose diet. Drug Metab. Dispos., 2008, 36(2), 294-302. (Pubitemid 351185741)
102. Okamura, K.; Ishii, Y.; Ikushiro, S.; Mackenzie, P. I.; Yamada, H. Fatty acyl-CoA as an endogenous activator of UDP-glucuronosyltransferases. Biochem. Biophys. Res. Commun., 2006, 345(4), 1649-1656. (Pubitemid 43817919)
103. Li, L. O.; Klett, E. L.; Coleman, R. A. Acyl-CoA synthesis, lipid metabolism and lipotoxicity. Biochim. Biophys. Acta., 2010, 1801(3), 246-251.
104. Wang, H.; LeCluyse, E. L. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet., 2003, 42(15), 1331-1357. (Pubitemid 38045840)
105. Tietge, U. J.; Boker, K. H.; Manns, M. P.; Bahr, M. J. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am. J. Physiol. Endocrinol. Metab., 2004, 287(1), E82-89. (Pubitemid 38856286)
106. Xu, C.; Li, C. Y.; Kong, A. N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res, 2005, 28(3), 249-268. (Pubitemid 44698742)
107. Hahn, M. E. Aryl hydrocarbon receptors: diversity and evolution. Chem. Biol. Interact., 2002, 141 (1-2), 131-160. (Pubitemid 35223209)
108. Li, W.; Harper, P. A.; Tang, B. K.; Okey, A. B. Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthrene. Biochem. Pharmacol., 1998, 56(5), 599-612. (Pubitemid 28458899)
109. Fisher, C. D.; Jackson, J. P.; Lickteig, A. J.; Augustine, L. M.; Cherrington, N. J. Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch. Toxicol., 2008, 82(12), 959-964.
110. La Merrill, M.; Kuruvilla, B. S.; Pomp, D.; Birnbaum, L. S.; Threadgill, D. W. Dietary fat alters body composition, mammary development, and cytochrome p450 induction after maternal TCDD exposure in DBA/2J mice with low-responsive aryl hydrocarbon receptors. Environ. Health Perspect., 2009, 117(9), 1414-1419.
111. Moriguchi, T.; Motohashi, H.; Hosoya, T.; Nakajima, O.; Takahashi, S.; Ohsako, S.; Aoki, Y.; Nishimura, N.; Tohyama, C.; Fujii-Kuriyama, Y.; Yamamoto, M. Distinct response to dioxin in an arylhydrocarbon receptor (AHR)-humanized mouse. Proc. Natl. Acad. Sci. U. S. A, 2003, 100(10), 5652-5657. (Pubitemid 36576863)
112. Kawano, Y.; Nishiumi, S.; Tanaka, S.; Nobutani, K.; Miki, A.; Yano, Y.; Seo, Y.; Kutsumi, H.; Ashida, H.; Azuma, T.; Yoshida, M. Activation of the aryl hydrocarbon receptor induces hepatic steatosis via the upregulation of fatty acid transport. Arch. Biochem. Biophys., 2010, 504(2), 221-227.
113. Maglich, J. M.; Stoltz, C. M.; Goodwin, B.; Hawkins-Brown, D.; Moore, J. T.; Kliewer, S. A. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol. Pharmacol., 2002, 62(3), 638-646. (Pubitemid 36329382)
114. Yoshinari, K.; Takagi, S.; Sugatani, J.; Miwa, M. Changes in the expression of cytochromes P450 and nuclear receptors in the liver of genetically diabetic db/db mice. Biol. Pharm. Bull., 2006, 29(8), 1634-1638. (Pubitemid 44166365)
115. Xiong, H.; Yoshinari, K.; Brouwer, K. L.; Negishi, M. Role of constitutive androstane receptor in the in vivo induction of Mrp3 and CYP2B1/2 by phenobarbital. Drug. Metab. Dispos., 2002, 30(8), 918-923. (Pubitemid 34815422)
116. Dong, B.; Saha, P. K.; Huang, W.; Chen, W.; Abu-Elheiga, L. A.; Wakil, S. J.; Stevens, R. D.; Ilkayeva, O.; Newgard, C. B.; Chan, L.; Moore, D. D. Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc. Natl. Acad. Sci. USA, 2009, 106(44), 18831-18836.
117. Xie, W.; Barwick, J. L.; Simon, C. M.; Pierce, A. M.; Safe, S.; Blumberg, B.; Guzelian, P. S.; Evans, R. M. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev., 2000, 14(23), 3014-3023.
118. Moore, J. T.; Moore, L. B.; Maglich, J. M.; Kliewer, S. A. Functional and structural comparison of PXR and CAR. Biochim. Biophys. Acta., 2003, 1619(3), 235-238. (Pubitemid 36160601)
119. Willson, T. M.; Kliewer, S. A. PXR, CAR and drug metabolism. Nat. Rev. Drug Discov., 2002, 1(4), 259-266. (Pubitemid 37361442)
120. Osabe, M.; Sugatani, J.; Fukuyama, T.; Ikushiro, S.; Ikari, A.; Miwa, M. Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferatoractivated receptor alpha in male rats fed a high-fat and high-sucrose diet. Drug Metab. Dispos., 2008, 36(2), 294-302. (Pubitemid 351185741)
121. Desvergne, B.; Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 1999, 20(5), 649-688. (Pubitemid 30650602)
122. Brown, J. D.; Plutzky, J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation, 2007, 115(4), 518-533. (Pubitemid 46184203)
123. Yoshinari, K.; Takagi, S.; Sugatani, J.; Miwa, M. Changes in the expression of cytochromes P450 and nuclear receptors in the liver of genetically diabetic db/db mice. Biol. Pharm. Bull., 2006, 29(8), 1634-1638. (Pubitemid 44166365)
124. Yoneda, M.; Endo, H.; Nozaki, Y.; Tomimoto, A.; Fujisawa, T.; Fujita, K.; Yoneda, K.; Takahashi, H.; Saito, S.; Iwasaki, T.; Yamamoto, S.; Tsutsumi, S.; Aburatani, H.; Wada, K.; Hotta, K.; Nakajima, A. Life style-related diseases of the digestive system: gene expression in nonalcoholic steatohepatitis patients and treatment strategies. J. Pharmacol. Sci., 2007, 105(2), 151-156. (Pubitemid 350106804)
125. Pawar, A.; Botolin, D.; Mangelsdorf, D. J.; Jump, D. B. The role of liver X receptor-alpha in the fatty acid regulation of hepatic gene expression. J. Biol. Chem., 2003, 278(42), 40736-40743. (Pubitemid 37280889)
126. Chakravarthy, M. V.; Lodhi, I. J.; Yin, L.; Malapaka, R. R.; Xu, H. E.; Turk, J.; Semenkovich, C. F. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell, 2009, 138(3), 476-488.
127. Khan, S. A.; Vanden Heuvel, J. P. Role of nuclear receptors in the regulation of gene expression by dietary fatty acids (review). J. Nutr. Biochem., 2003, 14(10), 554-567. (Pubitemid 37239008)
128. Vallim, T.; Salter, A. M. Regulation of hepatic gene expression by saturated fatty acids. Prostaglandins Leukot. Essent. Fatty Acids, 2010, 82 (4-6), 211-218.
129. Chen, G.; Liang, G.; Ou, J.; Goldstein, J. L.; Brown, M. S. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc. Natl. Acad. Sci. USA, 2004, 101(31), 11245-11250. (Pubitemid 39038332)
130. Lee, J. H.; Zhou, J.; Xie, W. PXR and LXR in hepatic steatosis: a new dog and an old dog with new tricks. Mol. Pharm., 2008, 5(1), 60-66. (Pubitemid 351300035)
131. Wouters, K.; van Bilsen, M.; van Gorp, P. J.; Bieghs, V.; Lutjohann, D.; Kerksiek, A.; Staels, B.; Hofker, M. H.; Shiri-Sverdlov, R. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett., 2010, 584(5), 1001-1005.
132. Cai, S. Y.; Boyer, J. L. FXR: a target for cholestatic syndromes? Expert Opin. Ther. Targets, 2006, 10(3), 409-421. (Pubitemid 43949955)
133. Lefebvre, P.; Cariou, B.; Lien, F.; Kuipers, F.; Staels, B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev., 2009, 89(1), 147-191.
134. Kwak, M. K.; Itoh, K.; Yamamoto, M.; Sutter, T. R.; Kensler, T. W. Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione. Mol. Med., 2001, 7(2), 135-145. (Pubitemid 33702029)
135. Lee, J. S.; Surh, Y. J. Nrf2 as a novel molecular target for
136. Lickteig, A. J.; Fisher, C. D.; Augustine, L. M.; Cherrington, N. J. Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis. J. Biochem. Mol. Toxicol., 2007, 21(4), 216-220. (Pubitemid 350194382)
137. Vollrath, V.; Wielandt, A. M.; Iruretagoyena, M.; Chianale, J. Role of Nrf2 in the regulation of the Mrp2 (ABCC2) gene. Biochem. J., 2006, 395(3), 599-609.
138. Aleksunes, L. M.; Slitt, A. L.; Maher, J. M.; Augustine, L. M.; Goedken, M. J.; Chan, J. Y.; Cherrington, N. J.; Klaassen, C. D.; Manautou, J. E. Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. Toxicol. Appl. Pharmacol., 2008, 226(1), 74-83. (Pubitemid 350235582)
139. Malaguarnera, L.; Madeddu, R.; Palio, E.; Arena, N.; Malaguarnera, M. Heme oxygenase-1 levels and oxidative stressrelated parameters in non-alcoholic fatty liver disease patients. J. Hepatol., 2005, 42(4), 585-591. (Pubitemid 40342940)